CoChat
Sign Up
Cited by 33Fibromyalgia and Chronic Fatigue Syndrome ResearchLong-Term Effects of COVID-19COVID-19 and Mental Health

Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?

Open access
Fialho, Maria Fernanda Pessano, Brum, Evelyne Silva, Oliveira, Sara Marchesan·2023·Inflammopharmacology
DOI 10.1007/s10787-023-01160-wPMC PMC9970139
Open this paper in CoChat — free accountOpen PDF

Abstract

Fibromyalgia (FM) is a complex disease with an uncertain aetiology and intricate pathophysiology. Although its genesis is not fully explained, potential environmental factors, such as viral infections might trigger FM or worsen patients' clinical outcomes. The SARS-CoV-2 virus may affect central and peripheral nervous systems, leading to musculoskeletal, neurological, and psychological disturbances. These symptoms might persist at least 12 months beyond the recovery, often referred to as post-COVID syndrome, which resembles FM syndrome. In this sense, we argued the potential consequences of COVID-19 exclusively on FM syndrome. First, we have described post-COVID syndrome and its painful symptoms. Afterwards, we argued whether FM syndrome could be triggered or enhanced by COVID-19 infection or by numerous and persistent stressors imposed daily by the pandemic setting (isolation, uncertainty, depression, mental stress, generalized anxiety, and fear of the virus). In addition, we have demonstrated similarities between pathophysiological mechanisms and cardinal symptoms of FM and COVID-19, speculating that SARS-CoV-2 might represent a critical mediator of FM or an exacerbator of its symptoms once both syndromes share similar mechanisms and complaints. Therefore, pharmacologic and non-pharmacological approaches commonly used to treat FM could serve as strategic therapies to attenuate painful and neurological manifestations of post-COVID syndrome. Although it is still theoretical, clinicians and researchers should be alert of patients who develop symptoms similar to FM or those who had their FM symptoms increased post-COVID to manage them better.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10787-023-01160-w

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 147

  1. Abani O Abbas A Abbas F Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Lancet 2021 397 1637 1645 10.1016/S0140-6736(21)00676-0 33933206 PMC8084355 · DOI · Paper page
  2. Abdullahi A Candan SA Abba MA Neurological and musculoskeletal features of COVID-19: a systematic review and meta-analysis Front Neurol 2020 11 72 83 10.3389/fneur.2020.00687 32676052 PMC7333777 · DOI
  3. Abidi E El Nekidy WS Alefishat E Tocilizumab and COVID-19: timing of administration and efficacy Front Pharmacol 2022 13 1 12 10.3389/fphar.2022.825749 PMC8894855 35250575 · DOI
  4. Ajaz S McPhail MJ Singh KK Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19 Am J Physiol Physiol 2021 320 C57 C65 10.1152/ajpcell.00426.2020 PMC7816428 33151090 · DOI
  5. Aksan F Nelson EA Swedish KA A COVID-19 patient with intense burning pain J Neurovirol 2020 26 800 801 10.1007/s13365-020-00887-4 32779108 PMC7416991 · DOI
  6. Aloush V Gurfinkel A Shachar N Physical and mental impact of COVID-19 outbreak on fibromyalgia patients Clin Exp Rheumatol 2021 130 108 114 10.55563/clinexprheumatol/rxk6s4 33734970 · DOI · Paper page
  7. Attal N Martinez V Bouhassira D Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic PAIN Reports 2021 6 884 10.1097/PR9.0000000000000884 PMC7850724 33537521 · DOI
  8. Bach DR Korn CW Vunder J Bantel A Effect of valproate and pregabalin on human anxiety-like behaviour in a randomised controlled trial Transl Psychiatry 2018 8 157 10.1038/s41398-018-0206-7 30115911 PMC6095858 · DOI
  9. Barnes PJ Glucocorticosteroids: current and future directions Br J Pharmacol 2011 163 29 43 10.1111/J.1476-5381.2010.01199.X 21198556 PMC3085866 · DOI
  10. Ben-Menachem E Pregabalin pharmacology and its relevance to clinical practice Epilepsia 2004 45 13 18 10.1111/j.0013-9580.2004.455003.x 15315511 · DOI
  11. Bjørklund G Dadar M Chirumbolo S Aaseth J Fibromyalgia and nutrition: therapeutic possibilities? Biomed Pharmacother 2018 103 531 538 10.1016/j.biopha.2018.04.056 29677539 · DOI
  12. Blanch-Rubió J Soldevila-Domenech N Tío L Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions Aging 2020 12 19923 19937 10.18632/aging.104117 33080571 PMC7655189 · DOI
  13. Bockbrader HN Wesche D Miller R A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin Clin Pharmacokinet 2010 49 661 669 10.2165/11536200-000000000-00000 20818832 · DOI
  14. Boldrini M Canoll PD Klein RS How COVID-19 Affects the Brain JAMA Psychiat 2021 78 682 10.1001/jamapsychiatry.2021.0500 PMC9894299 33769431 · DOI
  15. Busch A Barber K Overend T Busch A Exercise for treating fibromyalgia syndrome The cochrane database of systematic reviews (Protocol) 2002 Chichester John Wiley & Sons, Ltd 3786 PMC12832165 17943797
  16. Buskila D Atzeni F Sarzi-Puttini P Etiology of fibromyalgia: the possible role of infection and vaccination Autoimmun Rev 2008 8 41 43 10.1016/j.autrev.2008.07.023 18706528 · DOI
  17. Caiazzo E Rezig AOM Bruzzese D Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: a systematic review and meta-analysis of randomised trials Pharmacol Res 2022 176 106053 10.1016/J.PHRS.2021.106053 34979235 PMC8719379 · DOI
  18. Cankurtaran D Tezel N Ercan B The effects of COVID-19 fear and anxiety on symptom severity, sleep quality, and mood in patients with fibromyalgia: a pilot study Adv Rheumatol 2021 61 41 10.1186/s42358-021-00200-9 34193303 PMC8243054 · DOI
  19. Cano EJ Fonseca Fuentes X Corsini Campioli C Impact of corticosteroids in coronavirus disease 2019 outcomes Chest 2021 159 1019 1040 10.1016/j.chest.2020.10.054 33129791 PMC7598533 · DOI
  20. Cavalli G De Luca G Campochiaro C Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Lancet Rheumatol 2020 2 e325 e331 10.1016/S2665-9913(20)30127-2 32501454 PMC7252085 · DOI
  21. Cavalli G Cariddi A Ferrari J Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients Rheumatol 2021 60 465 467 10.1093/rheumatology/keaa738 PMC7717382 33188686 · DOI
  22. Cecchini R Cecchini AL SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression Med Hypotheses 2020 143 110102 10.1016/J.MEHY.2020.110102 32721799 PMC7357498 · DOI
  23. Chandan JS Brown K Simms-Williams N Protocol: non-pharmacological therapies for postviral syndromes, including Long COVID: a systematic review and meta-analysis protocol BMJ Open 2022 12 57885 10.1136/BMJOPEN-2021-057885 PMC9002258 35410933 · DOI
  24. Chang S Minn D Kim S-W Kim Y Inflammatory Markers and Cytokines in Moderate and Critical Cases of COVID-19 Clin Lab 2021 10.7754/Clin.Lab.2021.210142 34542974 · DOI
  25. Chen G Wu D Guo W Clinical and immunological features of severe and moderate coronavirus disease 2019 J Clin Invest 2020 130 2620 2629 10.1172/JCI137244 32217835 PMC7190990 · DOI · Paper page
  26. Chen X Zhao B Qu Y Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically Ill patients with coronavirus disease 2019 Clin Infect Dis 2020 71 1937 1942 10.1093/cid/ciaa449 32301997 PMC7184354 · DOI
  27. Clauw DJ Fibromyalgia and related conditions Mayo Clin Proc 2015 90 680 692 10.1016/j.mayocp.2015.03.014 25939940 · DOI · Paper page
  28. Clauw DJ Häuser W Cohen SP Fitzcharles M-A Considering the potential for an increase in chronic pain after the COVID-19 pandemic Pain 2020 161 1694 1697 10.1097/j.pain.0000000000001950 32701829 PMC7302093 · DOI
  29. Clemency BM Varughese R Gonzalez-Rojas Y Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial JAMA Intern Med 2022 182 42 49 10.1001/JAMAINTERNMED.2021.6759 34807241 PMC8609464 · DOI
  30. Cordero MD Cano-García FJ Alcocer-Gómez E Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q 10 effect on clinical improvement PLoS ONE 2012 7 6 11 10.1371/journal.pone.0035677 PMC3330812 22532869 · DOI
  31. Cordero MD Cotán D del-Pozo-Martín Y Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient Nutrition 2012 28 1200 1203 10.1016/j.nut.2012.03.018 22898267 · DOI
  32. Cordero MD Alcocer-Gómez E Culic O NLRP3 inflammasome is activated in fibromyalgia: the effect of coenzyme Q 10 Antioxid Redox Signal 2014 20 1169 1180 10.1089/ars.2013.5198 23886272 PMC3934515 · DOI
  33. Disser NP De Micheli AJ Schonk MM Musculoskeletal consequences of COVID-19 J Bone Jt Surg - Am 2020 102 1197 1204 10.2106/JBJS.20.00847 PMC7508274 32675661 · DOI
  34. dos Santos AAC Rodrigues LE Alecrim-Zeza AL Molecular and cellular mechanisms involved in tissue-specific metabolic modulation by SARS-CoV-2 Front Microbiol 2022 13 4553 10.3389/FMICB.2022.1037467/BIBTEX PMC9684198 36439786 · DOI
  35. Dotan A David P Arnheim D Shoenfeld Y The autonomic aspects of the post-COVID19 syndrome Autoimmun Rev 2022 10.1016/J.AUTREV.2022.103071 35182777 PMC8848724 · DOI
  36. Eisinger J Plantamura A Ayavou T Glycolysis abnormalities in fibromyalgia J Am Coll Nutr 1994 13 144 148 10.1080/07315724.1994.10718387 8006296 · DOI
  37. Elkan M Dvir A Zaidenstein R Patient-reported outcome measures after hospitalization during the COVID-19 pandemic: a survey among COVID-19 and non-COVID-19 patients Int J Gen Med 2021 14 4829 4836 10.2147/IJGM.S323316 34471377 PMC8405220 · DOI
  38. Ely EW Ramanan AV Kartman CE Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial Lancet Respir Med 2022 10 327 336 10.1016/S2213-2600(22)00006-6 35123660 PMC8813065 · DOI
  39. Fanelli D Weller G Liu H New serotonin-norepinephrine reuptake inhibitors and their anesthetic and analgesic considerations Neurol Int 2021 13 497 509 10.3390/NEUROLINT13040049 34698218 PMC8544373 · DOI
  40. Fasolino A Di Stefano G Leone C Small-fibre pathology has no impact on somatosensory system function in patients with fibromyalgia Pain Publish Ah: 2020 10.1097/j.pain.0000000000001920 32897040 · DOI
  41. Fernández-de-las-Peñas C De-la-Llave-Rincón AI Ortega-Santiago R Prevalence and risk factors of musculoskeletal pain symptoms as long-term post-COVID sequelae in hospitalized COVID-19 survivors Pain 2021 10.1097/j.pain.0000000000002564 34913880 · DOI
  42. Fernández-de-las-Peñas C Rodríguez-Jiménez J Fuensalida-Novo S Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study Pain 2021 162 2832 2840 10.1097/j.pain.0000000000002306 33863864 · DOI
  43. Fernández-de-las-Peñas C Navarro-Santana M Plaza-Manzano G Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis Pain 2022 163 1220 1231 10.1097/j.pain.0000000000002496 34561390 · DOI
  44. Fernández-de-las-Peñas C Cancela-Cilleruelo I Moro-López-Menchero P Exploring the trajectory curve of long-term musculoskeletal post-COVID pain symptoms in hospitalized COVID-19 survivors: a multicenter study Pain 2023 164 413 420 10.1097/j.pain.0000000000002718 35930390 · DOI
  45. Forcados GE Muhammad A Oladipo OO Metabolic implications of oxidative stress and inflammatory process in SARS-CoV-2 pathogenesis: therapeutic potential of natural antioxidants Front Cell Infect Microbiol 2021 11 654813 10.3389/fcimb.2021.654813 34123871 PMC8188981 · DOI
  46. Gentil P de Lira CAB Vieira CA Resistance training before, during, and after COVID-19 infection: what have we learned so far? Int J Environ Res Public Health 2022 10.3390/IJERPH19106323 35627861 PMC9141848 · DOI
  47. Godolphin PJ Fisher DJ Berry LR Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: a network meta-analysis PLoS ONE 2022 17 e0270668 10.1371/JOURNAL.PONE.0270668 35802687 PMC9269978 · DOI
  48. Gonzalez-Martinez A Guerrero-Peral ÁL Arias-Rivas S Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors J Neurol 2022 269 5702 5709 10.1007/S00415-022-11225-5/TABLES/4 35829760 PMC9553757 · DOI
  49. Goudman L De Smedt A Noppen M Moens M Is central sensitisation the missing link of persisting symptoms after COVID-19 infection? J Clin Med 2021 10.3390/JCM10235594 34884296 PMC8658135 · DOI
  50. Graham EL Clark JR Orban ZS Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers” Ann Clin Transl Neurol 2021 8 1073 1085 10.1002/acn3.51350 33755344 PMC8108421 · DOI · Paper page
  51. Guan W Ni Z Hu Y Clinical characteristics of coronavirus disease 2019 in China N Engl J Med 2020 382 1708 1720 10.1056/NEJMoa2002032 32109013 PMC7092819 · DOI · Paper page
  52. Harapan BN Yoo HJ Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) J Neurol 2021 268 3059 3071 10.1007/s00415-021-10406-y 33486564 PMC7826147 · DOI
  53. Harrington R Al Nokhatha SA Conway R JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data J Inflamm Res 2020 13 519 10.2147/JIR.S219586 32982367 PMC7500842 · DOI
  54. Häuser W Perrot S Sommer C Diagnostic confounders of chronic widespread pain: not always fibromyalgia PAIN Reports 2017 2 598 10.1097/PR9.0000000000000598 PMC5741304 29392213 · DOI
  55. Heesakkers H Van Der Hoeven JG Corsten S Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19 JAMA 2022 327 559 565 10.1001/JAMA.2022.0040 35072716 PMC8787680 · DOI
  56. Hernando-Garijo I Ceballos-Laita L Mingo-Gómez MT Immediate effects of a telerehabilitation program based on aerobic exercise in women with fibromyalgia Int J Environ Res Public Health 2021 18 1 12 10.3390/IJERPH18042075 PMC7924356 33672691 · DOI
  57. Horby PW Martin P Landray J Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Lancet Respir Med 2021 9 1419 1426 10.1016/S2213-2600(21)00435-5 34672950 PMC8523117 · DOI
  58. Hosey MM Needham DM Survivorship after COVID-19 ICU stay Nat Rev Dis Prim 2020 6 60 10.1038/s41572-020-0201-1 32669623 PMC7362322 · DOI
  59. Huang E Jordan SC Tocilizumab for Covid-19 — the ongoing search for effective therapies N Engl J Med 2020 383 2387 2388 10.1056/NEJME2032071/SUPPL_FILE/NEJME2032071_DISCLOSURES.PDF 33296566 PMC7745168 · DOI
  60. Huang L Yao Q Gu X 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study Lancet 2021 398 747 758 10.1016/S0140-6736(21)01755-4 34454673 PMC8389999 · DOI · Paper page
  61. Huet T Beaussier H Voisin O Anakinra for severe forms of COVID-19: a cohort study Lancet Rheumatol 2020 2 e393 e400 10.1016/S2665-9913(20)30164-8 32835245 PMC7259909 · DOI
  62. Hung C-H Lee C-H Tsai M-H Activation of acid-sensing ion channel 3 by lysophosphatidylcholine 16:0 mediates psychological stress-induced fibromyalgia-like pain Ann Rheum Dis 2020 79 1644 1656 10.1136/annrheumdis-2020-218329 32907805 PMC7677496 · DOI · Paper page
  63. Iannuccelli C Lucchino B Gioia C Mental health and well-being during the COVID-19 pandemic: stress vulnerability, resilience and mood disturbances in fibromyalgia and rheumatoid arthritis Clin Exp Rheumatol 2021 39 153 160 10.55563/clinexprheumatol/4nb0ku 34161226 · DOI
  64. Inoue S Hatakeyama J Kondo Y Post-intensive care syndrome: its pathophysiology, prevention, and future directions Acute Med Surg 2019 6 233 246 10.1002/ams2.415 31304024 PMC6603316 · DOI
  65. Jena D Sahoo J Barman A Neuropathic pain in hospitalized patients with COVID-19: a prospective case series Arch Rehabil Res Clin Transl. 2022 4 100188 10.1016/J.ARRCT.2022.100188 35252833 PMC8882261 · DOI
  66. Ji RR Nackley A Huh Y Neuroinflammation and central sensitization in chronic and widespread pain Anesthesiology 2018 129 343 366 10.1097/ALN.0000000000002130 29462012 PMC6051899 · DOI · Paper page
  67. Josephson SA Kamel H Neurology and COVID-19 JAMA 2020 324 1139 10.1001/jama.2020.14254 32960246 · DOI
  68. Kalil AC Patterson TF Mehta AK Baricitinib plus remdesivir for hospitalized adults with Covid-19 N Engl J Med 2021 384 795 807 10.1056/NEJMOA2031994/SUPPL_FILE/NEJMOA2031994_DATA-SHARING.PDF 33306283 PMC7745180 · DOI
  69. Kamimura D Ishihara K Hirano T IL-6 signal transduction and its physiological roles: the signal orchestration model Rev Physiol Biochem Pharmacol 2003 149 1 38 10.1007/S10254-003-0012-2 12687404 · DOI · Paper page
  70. Kayaaslan B Eser F Kalem AK Post-COVID syndrome: a single-center questionnaire study on 1007 participants recovered from COVID-19 J Med Virol 2021 93 6566 6574 10.1002/jmv.27198 34255355 PMC8426910 · DOI
  71. Kemp HI Laycock H Costello A Brett SJ Chronic pain in critical care survivors: a narrative review Br J Anaesth 2019 123 e372 e384 10.1016/j.bja.2019.03.025 31126622 PMC6676238 · DOI
  72. Kemp HI Corner E Colvin LA Chronic pain after COVID-19: implications for rehabilitation Br J Anaesth 2020 125 436 440 10.1016/j.bja.2020.05.021 32560913 PMC7261464 · DOI
  73. Kirito K Recent progress of JAK inhibitors for hematological disorders Immunol Med 2022 10.1080/25785826.2022.2139317 36305377 · DOI
  74. Komaroff AL Lipkin WI Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome Trends Mol Med 2021 27 895 906 10.1016/j.molmed.2021.06.002 34175230 PMC8180841 · DOI
  75. Kosek E Clauw D Nijs J Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system Pain 2021 162 2629 2634 10.1097/J.PAIN.0000000000002324 33974577 · DOI
  76. Kostorz-Nosal S Jastrzębski D Chyra M A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia Eur Clin Respir J 2021 10.1080/20018525.2021.1945186 34221256 PMC8231404 · DOI
  77. Krynytska I Marushchak M Birchenko I COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review) Iran J Microbiol. 2021 13 737 10.18502/IJM.V13I6.8072 35222850 PMC8816697 · DOI
  78. Kucuk A Cumhur Cure M Cure E Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis Clin Rheumatol 2020 39 2103 2104 10.1007/s10067-020-05178-1 32458242 PMC7249985 · DOI
  79. Kumar A Loharch S Kumar S Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2 Comput Struct Biotechnol J 2021 19 424 438 10.1016/J.CSBJ.2020.12.028 33391634 PMC7771909 · DOI
  80. Kutkat O Moatasim Y Al-Karmalawy AA Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies Sci Rep 2022 121 12 1 12 10.1038/s41598-022-17082-6 PMC9331004 35902647 · DOI
  81. Lamontagne F Agarwal A Rochwerg B A living WHO guideline on drugs for covid-19 BMJ 2020 370 m3379 10.1136/bmj.m3379 32887691 · DOI · Paper page
  82. Landewé RBM Machado PM Kroon F EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 Ann Rheum Dis 2020 79 851 858 10.1136/annrheumdis-2020-217877 32503854 · DOI
  83. Larson AA Pardo JV Pasley JD Review of overlap between thermoregulation and pain modulation in fibromyalgia Clin J Pain 2014 30 544 555 10.1097/AJP.0b013e3182a0e383 23887348 PMC3864605 · DOI
  84. Liguori C Pierantozzi M Spanetta M Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection Brain Behav Immun 2020 88 11 16 10.1016/j.bbi.2020.05.037 32416289 PMC7235586 · DOI · Paper page
  85. Liguori C Pierantozzi M Spanetta M Depressive and anxiety symptoms in patients with SARS-CoV2 infection J Affect Disord 2021 278 339 340 10.1016/j.jad.2020.09.042 32987349 PMC7489218 · DOI
  86. Littlejohn G Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome Nat Rev Rheumatol 2015 11 639 648 10.1038/nrrheum.2015.100 26241184 · DOI
  87. Littlejohn G Guymer E Neurogenic inflammation in fibromyalgia Semin Immunopathol 2018 40 291 300 10.1007/s00281-018-0672-2 29556959 · DOI
  88. Logue JK Franko NM McCulloch DJ Sequelae in adults at 6 months after COVID-19 infection JAMA Netw Open 2021 4 e210830 10.1001/jamanetworkopen.2021.0830 33606031 PMC7896197 · DOI
  89. López-Solà M Woo C-W Pujol J Towards a neurophysiological signature for fibromyalgia Pain 2017 158 34 47 10.1097/j.pain.0000000000000707 27583567 PMC5161739 · DOI
  90. Mao L Jin H Wang M Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China JAMA Neurol 2020 77 683 10.1001/jamaneurol.2020.1127 32275288 PMC7149362 · DOI · Paper page
  91. Marconi VC Ramanan AV de Bono S Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial Lancet Respir Med 2021 9 1407 1418 10.1016/S2213-2600(21)00331-3 34480861 PMC8409066 · DOI
  92. McFarland AJ Yousuf MS Shiers S Price TJ Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain Pain Reports. 2021 6 e885 10.1097/PR9.0000000000000885 33458558 PMC7803673 · DOI
  93. McLain D The effects of tizanidine HCL (Zanaflex®) in patients with fibromyalgia Pain Med 2000 1 207 207 10.1046/j.1526-4637.2000.000024-48.x · DOI
  94. Meeus M Nijs J Hermans L The role of mitochondrial dysfunctions due to oxidative and nitrosative stress in the chronic pain or chronic fatigue syndromes and fibromyalgia patients: peripheral and central mechanisms as therapeutic targets? Expert Opin Ther Targets 2013 17 1081 1089 10.1517/14728222.2013.818657 23834645 · DOI
  95. Meulders A Vlaeyen JWS Evers AWM Chronic primary pain in the COVID-19 pandemic: how uncertainty and stress impact on functioning and suffering Pain 2022 163 604 609 10.1097/J.PAIN.0000000000002428 34382606 · DOI
  96. Moghimi N Di Napoli M Biller J The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection Curr Neurol Neurosci Rep 2021 21 44 10.1007/s11910-021-01130-1 34181102 PMC8237541 · DOI
  97. Mogil JS Social modulation of and by pain in humans and rodents Pain 2015 156 S35 S41 10.1097/01.j.pain.0000460341.62094.77 25789435 · DOI
  98. Mohabbat AB Mohabbat NML Wight EC Fibromyalgia and chronic fatigue syndrome in the age of COVID-19 Mayo Clin Proc Innov Qual Outcomes 2020 4 764 766 10.1016/j.mayocpiqo.2020.08.002 33204998 PMC7661943 · DOI
  99. Nalleballe K Reddy Onteddu S Sharma R Spectrum of neuropsychiatric manifestations in COVID-19 Brain Behav Immun 2020 88 71 74 10.1016/j.bbi.2020.06.020 32561222 PMC7297688 · DOI · Paper page
  100. Napadow V LaCount L Park K Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity Arthritis Rheum 2010 62 2545 2555 10.1002/art.27497 20506181 PMC2921024 · DOI · Paper page
  101. Nasserie T Hittle M Goodman SN Assessment of the frequency and variety of persistent symptoms among patients with COVID-19 JAMA Netw Open 2021 4 e2111417 10.1001/jamanetworkopen.2021.11417 34037731 PMC8155823 · DOI · Paper page
  102. Nataf S An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19 J Med Virol 2020 92 1743 1744 10.1002/jmv.25826 32246784 PMC7228370 · DOI
  103. Nehme M Braillard O Chappuis F Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting Ann Intern Med 2021 174 1252 1260 10.7326/M21-0878 34224254 PMC8280535 · DOI
  104. Oddy C McCaul J Keeling P Pharmacological predictors of morbidity and mortality in COVID-19 J Clin Pharmacol 2021 61 1286 1300 10.1002/jcph.1878 33908637 PMC8242508 · DOI
  105. Oh T-K Song I-A Lee J Musculoskeletal disorders, pain medication, and in-hospital mortality among patients with COVID-19 in South Korea: a population-based cohort study Int J Environ Res Public Health 2021 18 6804 10.3390/ijerph18136804 34202825 PMC8295800 · DOI
  106. Oray M Abu Samra K Ebrahimiadib N Long-term side effects of glucocorticoids Expert Opin Drug Saf 2016 15 457 465 10.1517/14740338.2016.1140743 26789102 · DOI
  107. Park JH Niermann KJ Olsen NJ Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia Curr Rheumatol Rep 2000 2 131 140 10.1007/s11926-000-0053-3 11123050 · DOI
  108. Pektas S Gursoy C Demirbilek SG The use of pregabalin in Intensive Care Unit in the treatment of Covid-19-related pain and cough J Coll Physicians Surg Pak 2021 31 S143 S143 10.29271/jcpsp.2021.Supp2.S143 34271819 · DOI
  109. Perez J Niburski K Stoopler M Ingelmo P Telehealth and chronic pain management from rapid adaptation to long-term implementation in pain medicine: a narrative review PAIN Reports. 2021 6 e912 10.1097/pr9.0000000000000912 33981934 PMC8108593 · DOI
  110. Perico N Cortinovis M Suter F Remuzzi G Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents Lancet Infect Dis 2022 23 e22 e33 10.1016/S1473-3099(22)00433 36030796 PMC9411261 · DOI
  111. Plasencia-García BO Rico-Rangel MI Rodríguez-Menéndez G Drug-drug Interactions between COVID-19 treatments and antidepressants, mood stabilizers/anticonvulsants, and benzodiazepines: integrated evidence from 3 databases Pharmacopsychiatry 2021 10.1055/a-1492-3293 34171927 · DOI
  112. Rada M Qusairy Z Massip-Salcedo M Macip S Relevance of the bruton tyrosine kinase as a target for COVID-19 therapy Mol Cancer Res 2021 19 549 554 10.1158/1541-7786.MCR-20-0814 33328281 · DOI
  113. RECOVERY CG, Dexamethasone in hospitalized patients with Covid-19 N Engl J Med 2021 384 693 704 10.1056/NEJMoa2021436 32678530 PMC7383595 · DOI · Paper page
  114. Rinnerthaler M Bischof J Streubel MK Oxidative stress in aging human skin Biomolecules 2015 5 545 589 10.3390/biom5020545 25906193 PMC4496685 · DOI · Paper page
  115. Roschewski M Lionakis MS Sharman JP Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 Sci Immunol 2020 10.1126/SCIIMMUNOL.ABD0110 32503877 PMC7274761 · DOI
  116. Rowbotham MC Arendt-Nielsen L A year like no other: introduction to a special issue on COVID-19 and pain PAIN Rep 2021 6 e915 10.1097/PR9.0000000000000915 33997584 PMC8116039 · DOI
  117. Sabe M Dorsaz O Huguelet P Kaiser S Toxicity of psychotropic drugs in patients with COVID-19: a systematic review Gen Hosp Psychiatry 2021 70 1 9 10.1016/J.GENHOSPPSYCH.2021.02.006 33631694 PMC7890235 · DOI
  118. Salaffi F Giorgi V Sirotti S The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome Clin Exp Rheumatol 2021 39 S72 S77 10.55563/clinexprheumatol/dnxtch 33200740 · DOI
  119. Salama C Han J Yau L Tocilizumab in patients hospitalized with Covid-19 pneumonia N Engl J Med 2021 384 20 30 10.1056/NEJMOA2030340 33332779 PMC7781101 · DOI
  120. Saleh J Peyssonnaux C Singh KK Edeas M Mitochondria and microbiota dysfunction in COVID-19 pathogenesis Mitochondrion 2020 54 1 7 10.1016/j.mito.2020.06.008 32574708 PMC7837003 · DOI
  121. Sarzi-Puttini P Giorgi V Marotto D Atzeni F Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment Nat Rev Rheumatol 2020 16 645 660 10.1038/s41584-020-00506-w 33024295 · DOI
  122. Scherlinger M Felten R Gallais F Refining “Long-COVID” by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection Infect Dis Ther 2021 10 1747 1763 10.1007/s40121-021-00484-w 34245450 PMC8270770 · DOI
  123. Schweiger V Secchettin E Castellani C Comparison between acupuncture and nutraceutical treatment with migratens® in patients with fibromyalgia syndrome: a prospective randomized clinical trial Nutrients 2020 12 821 10.3390/nu12030821 32204554 PMC7146219 · DOI
  124. Shiers S Ray PR Wangzhou A ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects Pain 2020 161 2494 2501 10.1097/j.pain.0000000000002051 32826754 PMC7572821 · DOI
  125. Shipton EE Shipton EA Vitamin D deficiency and pain: clinical evidence of low levels of vitamin D and supplementation in chronic pain states Pain Ther 2015 4 67 10.1007/S40122-015-0036-8 25920326 PMC4470966 · DOI
  126. Slee A Nazareth I Bondaronek P Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis Lancet 2019 393 768 777 10.1016/S0140-6736(18)31793-8 30712879 · DOI · Paper page
  127. Tancheva L Petralia MC Miteva S Emerging neurological and psychobiological aspects of COVID-19 infection Brain Sci 2020 10 852 10.3390/brainsci10110852 33198412 PMC7696269 · DOI
  128. Tardif JC Bouabdallaoui N L’Allier PL Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial Lancet Respir Med 2021 9 924 932 10.1016/S2213-2600(21)00222-8 34051877 PMC8159193 · DOI
  129. Theoharides TC Tsilioni I Bawazeer M Mast cells, neuroinflammation and pain in fibromyalgia syndrome Front Cell Neurosci 2019 13 1 8 10.3389/fncel.2019.00353 31427928 PMC6687840 · DOI
  130. Townsend L Dowds J O’Brien K Persistent poor health after COVID-19 is not associated with respiratory complications or initial disease severity Ann Am Thorac Soc 2021 18 997 1003 10.1513/AnnalsATS.202009-1175OC 33413026 PMC8456724 · DOI
  131. Treede R-D Rief W Barke A Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International Classification of Diseases (ICD-11) Pain 2019 160 19 27 10.1097/j.pain.0000000000001384 30586067 · DOI · Paper page
  132. Tuzun S Keles A Okutan D Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19 Eur J Phys Rehabil Med 2021 57 653 662 10.23736/S1973-9087.20.06563-6 33393277 · DOI
  133. Üçeyler N Zeller D Kahn AK Small fibre pathology in patients with fibromyalgia syndrome Brain 2013 136 1857 1867 10.1093/brain/awt053 23474848 · DOI · Paper page
  134. Ursini F Ciaffi J Mancarella L Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey RMD Open 2021 7 e001735 10.1136/rmdopen-2021-001735 34426540 PMC8384499 · DOI
  135. Valiuddin H Skwirsk B Paz-Arabo P Acute transverse myelitis associated with SARS-CoV-2: a case-report Brain, Behav Immun Heal. 2020 5 100091 10.1016/j.bbih.2020.100091 PMC7275168 32835294 · DOI
  136. van de Veerdonk FL Giamarellos-Bourboulis E Pickkers P A guide to immunotherapy for COVID-19 Nat Med 2022 28 39 50 10.1038/s41591-021-01643-9 35064248 · DOI
  137. Varga TV Bu F Dissing AS Loneliness, worries, anxiety, and precautionary behaviours in response to the COVID-19 pandemic: a longitudinal analysis of 200,000 Western and Northern Europeans Lancet Reg Heal Eur. 2021 2 100020 10.1016/j.lanepe.2020.100020 PMC8042675 33870246 · DOI
  138. Vertigan AE Kapela SL Ryan NM Pregabalin and speech pathology combination therapy for refractory chronic cough a randomized controlled trial Chest 2016 149 639 648 10.1378/chest.15-1271 26447687 · DOI
  139. Wang D Hu B Hu C Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China JAMA 2020 323 1061 10.1001/jama.2020.1585 32031570 PMC7042881 · DOI · Paper page
  140. Wang EY Mao T Klein J Diverse functional autoantibodies in patients with COVID-19 Nature 2021 595 283 288 10.1038/s41586-021-03631-y 34010947 PMC13130511 · DOI
  141. Widyadharma IPE Dewi PR Wijayanti IAS Utami DKI Pain related viral infections: a literature review Egypt J Neurol Psychiatry Neurosurg 2020 56 105 10.1186/s41983-020-00238-4 PMC7610167 33169060 · DOI
  142. Wiersinga WJ Rhodes A Cheng AC Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review JAMA 2020 324 782 793 10.1001/jama.2020.12839 32648899 · DOI · Paper page
  143. Wiersinga WJ Rhodes A Cheng AC Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) JAMA 2020 324 782 10.1001/jama.2020.12839 32648899 · DOI · Paper page
  144. Xu C Rafique A Potocky T Differential binding of sarilumab and tocilizumab to IL-6Rα and effects of receptor occupancy on clinical parameters J Clin Pharmacol 2021 61 714 724 10.1002/JCPH.1795 33314148 · DOI
  145. Yu LM Bafadhel M Dorward J Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial Lancet 2021 398 843 855 10.1016/S0140-6736(21)01744-X 34388395 PMC8354567 · DOI
  146. Zamorano Cuervo N Grandvaux N ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities Elife 2020 9 61390 10.7554/eLife.61390 PMC7652413 33164751 · DOI
  147. Zhang W Qin C Fei Y Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: an update Clin Immunol 2022 239 109022 10.1016/J.CLIM.2022.109022 35477027 PMC9040414 · DOI

Cited by

Sorted by citations

Authors
Fialho, M. F. P., Brum, E. S., & Oliveira, S. M.
Affiliations
Universidade Federal de Santa Maria (BR)
Corresponding author
Oliveira, Sara Marchesan
ORCID
Venue
Inflammopharmacology
Publisher
Springer Science and Business Media LLC
Published
2023-02-27
Volume
31
Issue
2
Pages
633-651
ISSN
  • 0925-4692 (ISSN-L)
  • 1568-5608
DOI
10.1007/s10787-023-01160-w
PMC
PMC9970139
OpenAlex
W4322418746
Cited by
33
References
22
Citations by year
2026: 5 · 2025: 8 · 2024: 16 · 2023: 4
FWCI
1.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Inflammopharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (#21/2551-0001966-2)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (304985/2020-1, #150611/2022-6)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (process #23038.002125/2021-85, Grant #0036/2021, #88882.182170/2018-01)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
  • Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
Keywords
fibromyalgia, COVID-19 pandemic, SARS-CoV-2, long COVID, psychological stress, depression, anxiety, isolation, neurological symptoms, musculoskeletal pain, pathophysiological mechanisms, fibromyalgia treatment
MeSH terms
COVID-19, SARS-CoV-2, Fibromyalgia, Humans, Pain, Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review